TRXC - TransEnterix, Inc.

NYSE American - NYSE American Delayed Price. Currency in USD
2.7600
+0.0500 (+1.85%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close2.7100
Open2.7600
Bid0.00 x 1200
Ask0.00 x 1100
Day's Range2.7100 - 2.7700
52 Week Range1.3900 - 6.9800
Volume1,534,992
Avg. Volume2,766,045
Market Cap596.488M
Beta (3Y Monthly)3.57
PE Ratio (TTM)N/A
EPS (TTM)-0.65
Earnings DateFeb 26, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.00
Trade prices are not sourced from all markets
  • Business Wire5 days ago

    TransEnterix Schedules Fourth Quarter and Fiscal Year 2018 Financial and Operating Results Conference Call for February 26, 2019

    TransEnterix, Inc. announced today that it plans to release fourth quarter and fiscal year 2018 financial and operating results before the market opens on Tuesday, February 26, 2019.

  • Why TransEnterix Gained 17.1% in 2018
    Motley Foollast month

    Why TransEnterix Gained 17.1% in 2018

    TransEnterix was one of the few biotech stocks to escape the market's wrath last year. Here's why.

  • Business Wirelast month

    TransEnterix Receives FDA 510(k) Clearance for Senhance Ultrasonic System

    TransEnterix, Inc. (NYSE American:TRXC), a medical device company that is digitizing the interface between surgeons and patients to improve minimally invasive surgery, today announced the Company received FDA 510(k) clearance for its Senhance™ Ultrasonic System. “Advanced energy devices are used within a high percentage of cases across a wide range of procedures, which make them a critical tool for laparoscopic surgeons,” said Todd M. Pope, TransEnterix president and CEO.

  • Here's Why TransEnterix Stock Tanked 27.3% in December
    Motley Foollast month

    Here's Why TransEnterix Stock Tanked 27.3% in December

    A market downturn that hit biotech stocks across the board and a dilutive share offering pressured shares of the robotic surgery upstart.

  • What’s Driving TransEnterix Stock on January 8?
    Market Realistlast month

    What’s Driving TransEnterix Stock on January 8?

    On January 8, TransEnterix (TRXC) rose 11.15% compared to its previous closing price and reached $2.99 in its pre-market trading session. On January 7, TransEnterix issued a press release announcing its preliminary operational and financial performance for the fourth quarter and fiscal 2018. Based on the closing price on January 7, TransEnterix reported returns of 9.80% in the last week, -13.50% in the last month, and -53.70% in the last quarter.

  • Why Transenterix Is Soaring Today
    Motley Foollast month

    Why Transenterix Is Soaring Today

    Shares jumped after the company provided investors with a slew of positive updates. Here are the key takeaways for investors.

  • Business Wirelast month

    TransEnterix Provides Corporate Update

    TransEnterix, Inc. (NYSE American: TRXC), a medical device company that is digitizing the interface between surgeons and patients to improve minimally invasive surgery, today provided a corporate update, including preliminary unaudited revenue for the fourth quarter ended December 31, 2018. “2018 was a significant year for TransEnterix as we continued to drive the global commercial adoption of the Senhance System and made great strides towards expanding the applicability of the system to a greater number of surgeons and hospitals across the globe," said Todd M. Pope, president and CEO at TransEnterix.

  • From Iqvia to Red Hat: These execs raked in millions from stock sales in 2018
    American City Business Journalslast month

    From Iqvia to Red Hat: These execs raked in millions from stock sales in 2018

    From Iqvia to Red Hat to Xerium Technologies, executives and investors at top Triangle firms raked in millions by selling shares in 2018, U.S. Securities and Exchange Commission filings show.

  • Are Insiders Selling TransEnterix, Inc. (NYSEMKT:TRXC) Stock?
    Simply Wall St.2 months ago

    Are Insiders Selling TransEnterix, Inc. (NYSEMKT:TRXC) Stock?

    We often see insiders buying up shares in companies that perform well over the long term. On the other hand, we'd be remiss not to mention that insider sales have Read More...

  • Transenterix Inc (TRXC): Hedge Funds Are Snapping Up
    Insider Monkey2 months ago

    Transenterix Inc (TRXC): Hedge Funds Are Snapping Up

    Is Transenterix Inc (NYSEMKT:TRXC) a good stock to buy right now? We at Insider Monkey like to examine what billionaires and hedge funds think of a company before doing days of research on it. Given their 2 and 20 payment structure, hedge funds have more resources than the average investor. The funds have access to […]

  • Business Wire2 months ago

    TransEnterix to Present at the 37th Annual J. P. Morgan Healthcare Conference

    TransEnterix, Inc. announced today that Todd M. Pope, President and Chief Executive Officer, and Joseph P. Slattery, Executive Vice President and Chief Financial Officer, will present at the 37th Annual J.P.

  • Are Options Traders Betting on a Big Move in TransEnterix (TRXC) Stock?
    Zacks2 months ago

    Are Options Traders Betting on a Big Move in TransEnterix (TRXC) Stock?

    Investors need to pay close attention to TransEnterix (TRXC) stock based on the movements in the options market lately.

  • Intuitive Surgical Stock Has Seen Growth of 34% Year-to-Date
    Market Realist3 months ago

    Intuitive Surgical Stock Has Seen Growth of 34% Year-to-Date

    Intuitive Surgical’s (ISRG) stock price rose from $364.94 at the close of market on December 29, 2017, to $489.57 on November 23, 2018, reflecting a ~34% year-to-date rise.

  • Thomson Reuters StreetEvents3 months ago

    Edited Transcript of TRXC earnings conference call or presentation 8-Nov-18 9:30pm GMT

    Q3 2018 Transenterix Inc Earnings Call

  • Business Wire3 months ago

    TransEnterix Named to Deloitte’s Technology Fast 500

    TransEnterix, Inc. (NYSE American:TRXC), a medical device company that is digitizing the interface between surgeons and patients to improve minimally invasive surgery, today announced its naming to Deloitte’s 2018 Technology Fast 500TM, an annual ranking of the fastest growing North American companies in the technology, media, telecommunications, life sciences and energy tech sectors. “We’re thrilled to be recognized as one of Deloitte’s 2018 Technology Fast 500 companies,” said Todd M. Pope, TransEnterix president and CEO. “TransEnterix’s mission is to advance minimally invasive surgical capabilities through digital laparoscopy with the SenhanceTM Surgical System.

  • Gauging Analysts’ Views on TransEnterix Stock
    Market Realist3 months ago

    Gauging Analysts’ Views on TransEnterix Stock

    In November, of the five analysts covering TransEnterix (TRXC), three have given it “buy” or higher ratings, and two have given it “hold” ratings. 

  • What TransEnterix’s Bottom Line Trend Indicates
    Market Realist3 months ago

    What TransEnterix’s Bottom Line Trend Indicates

    TransEnterix’s (TRXC) interest expense increased to $685,000 in the third quarter compared to $563,000 in the previous year’s period. TransEnterix’s net income rose from -$38.51 million in the third quarter of 2017 to -$20.21 million in the third quarter, translating to net EPS of -$0.10 in the third quarter. TransEnterix’s net EPS were -$0.26 in the third quarter of 2017.

  • Understanding TransEnterix’s Operational Performance
    Market Realist3 months ago

    Understanding TransEnterix’s Operational Performance

    For 2018 and 2019, TransEnterix’s gross margins are expected to be 41.40% and 48.76%, respectively, compared to its gross margin of 5.4% in 2017. In comparison, the 2018 gross margins of its peers Intuitive Surgical (ISRG), Johnson & Johnson (JNJ), and Stryker (SYK) are expected to be 71.01%, 70.43%, and 66.29%, respectively. TransEnterix incurred general and administrative expenses of $3.69 million in the third quarter compared to $2.92 million in the third quarter of 2017 primarily due to higher personnel costs and outsourced services expenses.

  • How TransEnterix Has Been Performing in November
    Market Realist3 months ago

    How TransEnterix Has Been Performing in November

    TransEnterix (TRXC) is a medical device company focused on digitizing the interface between surgeons and patients for the improvement of minimally invasive surgery. TransEnterix’s Senhance surgical system digitizes laparoscopic minimally invasive surgery and allows for robotic precision, haptic feedback, surgeon camera control, and improved ergonomics. TransEnterix generated total revenue of $5.42 million in the third quarter compared to $183,000 in the comparable period of 2017.

  • TransEnterix (TRXC) Reports Q3 Loss, Tops Revenue Estimates
    Zacks3 months ago

    TransEnterix (TRXC) Reports Q3 Loss, Tops Revenue Estimates

    TransEnterix (TRXC) delivered earnings and revenue surprises of 14.29% and 6.65%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press3 months ago

    TransEnterix: 3Q Earnings Snapshot

    On a per-share basis, the Morrisville, North Carolina-based company said it had a loss of 10 cents. Losses, adjusted for non-recurring costs and amortization costs, were 6 cents per share. The maker of ...

  • Business Wire3 months ago

    TransEnterix, Inc. Reports Operating and Financial Results for the Third Quarter 2018

    TransEnterix, Inc. , a medical device company that is digitizing the interface between the surgeon and the patient to improve minimally invasive surgery, today announced its operating and financial results for the third quarter 2018.

  • The most valuable public companies in the Triangle (Slideshow)
    American City Business Journals3 months ago

    The most valuable public companies in the Triangle (Slideshow)

    The number of public companies based in the Triangle has shrunk in recent years as acquisitions have meant a change in headquarters location, or even taking the company private.

  • Why TransEnterix, Inc. Sank 43.6% in October
    Motley Fool3 months ago

    Why TransEnterix, Inc. Sank 43.6% in October

    An early progress report couldn't help the robotic-surgery stock hang on to previous gains.

  • Will New Products Drive TransEnterix's (TRXC) Q3 Earnings?
    Zacks4 months ago

    Will New Products Drive TransEnterix's (TRXC) Q3 Earnings?

    Among the recent developments, in the third quarter, TransEnterixs (TRXC) gains an FDA approval for its additional 5 millimeter Senhance System instruments.